SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-043932
Filing Date
2023-12-07
Accepted
2023-12-07 06:01:47
Documents
16
Period of Report
2023-12-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44943
2 ex99-1.htm EX-99.1 34532
3 ex99-2.htm EX-99.2 1043
4 ex99-1_001.jpg GRAPHIC 8599
5 ex99-2_001.jpg GRAPHIC 186390
  Complete submission text file 0001493152-23-043932.txt   531242

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE anix-20231206.xsd EX-101.SCH 3006
7 XBRL LABEL FILE anix-20231206_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE anix-20231206_pre.xml EX-101.PRE 22353
10 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3333
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

IRS No.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 231471000
SIC: 2834 Pharmaceutical Preparations